|Bid||0.00 x 800|
|Ask||0.00 x 900|
|Day's Range||10.78 - 11.70|
|52 Week Range||6.44 - 23.29|
|Beta (3Y Monthly)||N/A|
|PE Ratio (TTM)||N/A|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||28.33|
WEST CHESTER, Pa., Feb. 12, 2019 -- Verrica Pharmaceuticals Inc. (Verrica) (Nasdaq: VRCA), a pharmaceutical company focused on the development of innovative pharmaceutical.
Verrica Pharmaceuticals Inc. (“Verrica”) (VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced the appointment of Neil D. DeHenes as Vice President of Distribution, Trade and Channel Strategy. "We are delighted to welcome Neil to our team and look forward to leveraging his deep industry experience as the company prepares for the potential launch of VP-102 for molluscum contagiosum," commented Ted White, President and Chief Executive Officer of Verrica. Mr. DeHenes brings to Verrica extensive experience in end-to-end commercialization support across the design, evaluation, implementation, and execution of channel strategy, patient services, co-pay offerings, third party logistics, and government program operations.
The company posted positive results from two late-stage studies of its experimental treatment for a highly contagious skin disease that afflicts primarily children.
WEST CHESTER, Pa., Jan. 03, 2019 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (Verrica) (VRCA), a pharmaceutical company focused on identifying, developing and commercializing innovative pharmaceutical products for the treatment of skin diseases with significant unmet needs, today announced positive topline results from its Phase 3 CAMP-1 and CAMP-2 pivotal trials with VP-102 for the treatment of molluscum contagiosum (molluscum). Both clinical trials evaluated the safety and efficacy of VP-102, a proprietary drug-device combination containing a novel topical solution of 0.7% cantharidin, compared to placebo. In each trial, VP-102 exhibited a clinically and statistically significant proportion of subjects demonstrating complete clearance of all treatable molluscum lesions versus placebo.
We often see insiders buying up shares in companies that perform well over the long term. The flip side of that is that there are more than a few examples Read More...
Malvern biopharmaceutical company PhaseBio has become the third local life sciences company to go public through an IPO in 2018.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Sept. 12). Inogen Inc (NASDAQ: INGN ) Kezar Life Sciences Inc ...
Investors who bought into Verrica Pharmaceuticals Inc (NASDAQ: VRCA ) at its June 15 IPO are celebrating 13.1-percent returns. The gains should continue, in the view of two new sell-side bulls. The Ratings ...